RenaissanceRe (RNR) Projected to Announce Quarterly Earnings on Tuesday

RenaissanceRe (NYSE:RNR) is expected to issue its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to post earnings of $10.33 per share and revenue of $1.78 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 11:00 AM ET.

RenaissanceRe (NYSE:RNR) last posted its quarterly earnings results on Tuesday, June 30th. The insurance provider reported $12.92 EPS for the quarter. The business had revenue of $2.77 billion during the quarter. RenaissanceRe had a return on equity of 23.10% and a net margin of 23.65%. On average, analysts expect RenaissanceRe to post $45.66 EPS for the current fiscal year and $41.01 EPS for the next fiscal year.

RenaissanceRe Price Performance

Shares of NYSE RNR opened at $351.53 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average price is $328.24 and its two-hundred day moving average price is $314.56. The company has a market cap of $14.61 billion, a PE ratio of 6.03, a price-to-earnings-growth ratio of 0.98 and a beta of 0.12. RenaissanceRe has a twelve month low of $231.17 and a twelve month high of $352.20.

RenaissanceRe Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th were given a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, September 15th. RenaissanceRe’s dividend payout ratio (DPR) is presently 2.81%.

Insider Buying and Selling at RenaissanceRe

In other news, EVP Robert Qutub sold 5,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $333.03, for a total transaction of $1,665,150.00. Following the sale, the executive vice president directly owned 72,907 shares of the company’s stock, valued at approximately $24,280,218.21. This represents a 6.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on RNR. UBS Group set a $349.00 target price on RenaissanceRe and gave the stock a “neutral” rating in a report on Monday, July 27th. Wells Fargo & Company dropped their price target on RenaissanceRe from $331.00 to $319.00 and set an “equal weight” rating on the stock in a research note on Monday, October 12th. Royal Bank Of Canada started coverage on RenaissanceRe in a report on Tuesday, September 22nd. They set a “sector perform” rating and a $365.00 price target for the company. Mizuho increased their price target on shares of RenaissanceRe from $325.00 to $329.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Finally, Barclays increased their target price on RenaissanceRe from $328.00 to $341.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 7th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $337.50.

About RenaissanceRe

RenaissanceRe Holdings Ltd. is a global provider of reinsurance and insurance products. The company specializes in helping insurers, businesses and other organizations manage financial risk arising from natural catastrophes, specialty exposures and certain casualty risks.

RenaissanceRe’s reinsurance activities include property catastrophe coverage, as well as casualty and specialty reinsurance. Through its insurance operations, the company provides coverage for areas such as property, casualty and other specialty risks.